ADICET-ADI-001-BCELL
Phase I
OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies
ADP-0000-001-SCR
Phase N/A
OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
ADP-0044-002-SPEARHEAD-1
Phase II
OPEN TO ACCRUAL
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ADP-0055-001-MAGE-A4-SURPASS
Phase I
OPEN TO ACCRUAL
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 as Monotherapy or in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
ALLOVIR-AVM-003-HC
Phase III
OPEN TO ACCRUAL *
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplant
ARCELLX-ACLX-001-DDBCMA
Phase I
OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
CARSGEN-CT041-ST-02
Phase I
OPEN TO ACCRUAL *
Open-Label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
CARSGEN-CT053-MM-02
Phase I/II
OPEN TO ACCRUAL
Open Label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
CELGENE-GC-LTFU-001
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-up Protocol for Subjects treated with Gene-Modified T Cells
FATE-FT576-101-MM
Phase I
OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
GSK-3377794-LTFU
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
INCYTE-INCB-39110-211-CRS
Phase II
OPEN TO ACCRUAL
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome (CRS) Induced by Immune Effector Cell Therapy
JNJ-MY4002-CARTINUE-LTFU
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
JUNO-017004-TRANSCEND-CLL
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
LYELL-LYL-797-101
Phase I
OPEN TO ACCRUAL
A Phase 1 Study to Assess the Safety of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid- Tumor Malignancies
SOTIO-BOXR1030
Phase I/II
OPEN TO ACCRUAL *
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors